A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576

Alberts SR, Gores GJ, Kim GP et al (2007) Treatment options for hepatobiliary and pancreatic cancer. Mayo Clin Proc 82:628–637

Shimoda M, Kubota K (2007) Multi-disciplinary treatment for cholangiocellular carcinoma. World J Gastroenterol 13:1500–1504

Bartlett D, Ramanathan RK, Ben-Joseph E (2008) Gallbladder and bilary cancers. In: Devita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 8th edn. Lippincott, Philadelphia

Berasain C, Castillo J, Prieto J et al (2007) New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver Int 27:174–185

Bekaii-Saab T, Williams N, Plass C et al (2006) A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC Cancer 6:278

Yoon JH, Gwak GY, Lee HS et al (2004) Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol 41:808–814

Sirica A (2005) Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 41:5–15

Philip PA, Mahoney MR, Allmer C et al (2005) Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23:6657–6663

Thomas MB, Chadha R, Glover K et al (2007) Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110:1059–1067

Philip PA, Mahoney MR, Allmer C et al (2006) Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 24:3069–3074

Reid A, Vidal L, Shaw H et al (2007) Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 43:481–489

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216

Simon R (1989) Optimal two-stage design for phase II clinical trials. Control Clin Trials 10:1–10

Gautschi O, Huegli B, Ziegler A et al (2007) Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett 254:265–273

Zhang W, Park DJ, Lu B et al (2005) Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. Clin Cancer Res 11:600–605

Matsuo M, Sakurai H, Saiki I (2003) ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. Mol Cancer Ther 2:557–561

Schiffer E, Housset C, Cacheux W et al (2005) Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 41:307–314

Zhu AX, Stuart K, Blaszkowsky LS et al (2007) Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 110:581–589

Llovet JM, Ricci S, Mazzaferro V, SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390

Peréz-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23:5235–5246

Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743

Press MF, Finn RS, Cameron D et al (2008) HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res 14:7861–7870

Van Cutsem E, Lang I, D’haens G et al (2008) KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol 26(May 20 suppl), abstr 2

Weihrauch M, Benicke M, Lehnert G et al (2001) Frequent k-ras-2 mutations and p16INK4Amethylation in hepatocellular carcinomas in workers exposed to vinyl chloride. Br J Cancer 84:982–989

Mayoral R, Fernandez-Martinez A, Bosca L et al (2005) Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells. Carcinogenesis 26:753–761

Mitchell C, Nivison M, Jackson LF et al (2005) Heparin-binding epidermal growth factor-like growth factor links hepatocyte priming with cell cycle progression during liver regeneration. J Biol Chem 280:2562–2568

Buerger H, Gebhardt F, Schmidt H et al (2000) Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 60:854–857

Gebhardt F, Zanker KS, Brandt B (1999) Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 274:13176–13180

Llovet JM, Di Bisceglie AM, Bruix J et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711